Current follow‐up practices often fail to detect metabolic and neurological adverse reactions in children treated with second‐generation antipsychotics

This study examined the use and adverse reactions of second‐generation antipsychotics (SGAs), alone or combined with other psychotropic medication, to identify areas for standardising prescribing and monitoring practices.

[1]  K. Murray,et al.  Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths , 2019, JAMA psychiatry.

[2]  K. Lehtimäki,et al.  Tardive Dyskinesia Should Not Be Overlooked. , 2019, Journal of child and adolescent psychopharmacology.

[3]  J. Iida,et al.  Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy , 2018, Journal of child and adolescent psychopharmacology.

[4]  J. Newcomer,et al.  Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial , 2018, JAMA psychiatry.

[5]  L. Creel,et al.  Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015 , 2018, Journal of managed care & specialty pharmacy.

[6]  A. Sourander,et al.  National time trend changes in psychotropic medication of child and adolescent psychiatric inpatients across Finland , 2018, Child and adolescent mental health.

[7]  C. Goldie,et al.  Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics , 2018, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[8]  T. Pringsheim,et al.  Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada , 2018, Clinical Drug Investigation.

[9]  H. Akbari,et al.  Effect of melatonin in reducing second-generation antipsychotic metabolic effects: A double blind controlled clinical trial. , 2018, Diabetes & metabolic syndrome.

[10]  N. Bilenberg,et al.  Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. , 2017, Journal of child and adolescent psychopharmacology.

[11]  I. Petersen,et al.  A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012 , 2017, Child and Adolescent Psychiatry and Mental Health.

[12]  S. Patten,et al.  Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study , 2017, Journal of clinical psychopharmacology.

[13]  P. de Castro-Manglano,et al.  Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate. , 2017, Journal of child and adolescent psychopharmacology.

[14]  S. Daniels,et al.  Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents , 2017, Pediatrics.

[15]  Mohammad Reza Mohammadi,et al.  Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. , 2017, Journal of child and adolescent psychopharmacology.

[16]  S. Brand,et al.  Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed – Results from a randomized, double-blind, placebo-controlled clinical trial , 2017, Psychiatry Research.

[17]  K. Puura,et al.  Clinical use of second-generation antipsychotics in children , 2017 .

[18]  Silja Martikainen,et al.  Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. , 2016, Cell metabolism.

[19]  M. Olfson,et al.  Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. , 2016, JAMA psychiatry.

[20]  J. Buitelaar,et al.  The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research , 2015, CNS Drugs.

[21]  J. Alda,et al.  Neurological Adverse Effects of Antipsychotics in Children and Adolescents , 2015, Journal of clinical psychopharmacology.

[22]  C. Correll,et al.  Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. , 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

[23]  Sepheen C. Byron,et al.  Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines. , 2014, Academic pediatrics.

[24]  S. Frangou,et al.  Antipsychotics use in children and adolescents: An on-going challenge in clinical practice , 2014, Journal of psychopharmacology.

[25]  S. Owens,et al.  Childhood Obesity and the Metabolic Syndrome , 2013, Current Atherosclerosis Reports.

[26]  J. Martínez-Ortega,et al.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review , 2013, European Child & Adolescent Psychiatry.

[27]  J. Rasimas,et al.  Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner. , 2012, Clinical pediatric emergency medicine.

[28]  C. Panagiotopoulos,et al.  Waist Circumference is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated with Second-Generation Antipsychotics , 2012, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[29]  L. Dunkel,et al.  New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age , 2011, Annals of medicine.

[30]  W. Dietz,et al.  Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of pediatrics & adolescent medicine.